Cancer Cachexia Market Revenue to Reach US$ 3.0 Billion by 2032, CAGR of 4.1% | IMARC Group

IMARC Group's report titled "Cancer Cachexia Market Report by Therapeutics (Progestogens, Corticosteroids, Combination Therapy, and Others), Mode of Action (Appetite Stimulators, Weight Loss Stabilizers), Distribution Channel (Hospital Stores, Retail Pharmacy, Online Pharmacy), and Region 2024-2032". The global cancer cachexia market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.0 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/cancer-cachexia-market/requestsample

Factors Affecting the Growth of Cancer Cachexia Industry:

• Increasing Cancer Prevalence and Diagnosis Rates:

Cancer cachexia is a severe and debilitating condition that often accompanies advanced stages of cancer. One of the primary factors driving the market for cancer cachexia treatment is the global increase in cancer prevalence and diagnosis rates. According to the World Cancer Research Fund, cancer is one of the leading causes of morbidity and mortality worldwide, with millions of new cases diagnosed each year. As more individuals are diagnosed with cancer and receive treatment, the incidence of cancer cachexia is also on the rise. The link between cancer and cachexia is well-established, with estimates suggesting that up to 80% of advanced cancer patients may experience cachexia. This has created a substantial patient population in need of effective therapies to manage and alleviate the debilitating symptoms associated with cachexia. As the healthcare community becomes increasingly aware of the importance of addressing cachexia as part of cancer care, there is a growing demand for innovative treatments and interventions, which in turn fuels research and development efforts in the field.

• Advancements in Oncology and Supportive Care:

Another key factor driving the cancer cachexia market is the continuous advancements in oncology treatments and supportive care strategies. Over the past few decades, there have been significant breakthroughs in cancer therapies, including targeted therapies, immunotherapies, and precision medicine approaches. These treatments aim to combat cancer itself and also have the potential to improve patient outcomes by reducing the severity of cachexia or preventing its onset. Additionally, healthcare providers have placed greater emphasis on supportive care, which includes addressing the nutritional and quality-of-life aspects of cancer patients. This holistic approach to cancer management involves the integration of nutrition counseling, exercise regimens, and pharmaceutical interventions to mitigate cachexia-related symptoms and enhance patients' overall well-being. As these supportive care strategies evolve and become more personalized, they contribute to the growth of the cancer cachexia market by offering new avenues for treatment and management.

• Increased Investment in Research and Development:

The third driving factor for the cancer cachexia market is the escalating investment in research and development (R&D) by pharmaceutical companies, academic institutions, and biotechnology firms. Recognizing the significant unmet medical needs of cancer cachexia patients, these stakeholders are actively pursuing innovative solutions. The growing understanding of the molecular mechanisms underlying cachexia and its impact on cancer patients has spurred a wave of interest in developing targeted therapies. Investment in R&D has led to the identification of potential drug candidates and the initiation of clinical trials aimed at testing their efficacy in treating cachexia. Moreover, collaborations and partnerships between industry players and research institutions have facilitated the sharing of knowledge and resources, expediting the development process. As promising candidates progress through the pipeline and gain regulatory approvals, the market for cancer cachexia treatments is poised for further expansion.

Leading Companies Operating in the Global Cancer Cachexia Industry:

• AAVogen Inc.
• Actimed Therapeutics Ltd.
• Aphios Corporation
• Artelo Biosciences Inc.
• AVEO Pharmaceuticals Inc.
• Fresenius Kabi AG (Fresenius SE & Co. KGaA)
• Helsinn Healthcare SA
• Merck & Co. Inc.
• NGM Biopharmaceuticals Inc.
• Pfizer Inc.
• Tetra Bio-Pharma

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/cancer-cachexia-market

Cancer Cachexia Market Report Segmentation:

By Therapeutics:

• Progestogens
• Corticosteroids
• Combination Therapy
• Others

Progestogens dominates the market due to their widespread use in various medical applications, including hormone replacement therapy, contraception, and the treatment of gynecological disorders, making them a versatile and essential component of healthcare.

By Mode of Action:

• Appetite Stimulators
• Weight Loss Stabilizers

Weight loss stabilizers hold maximum number of shares due to its crucial role in preventing and maintaining weight loss, making it a fundamental component of weight management strategies.

By Distribution Channel:

• Hospital Stores
• Retail Pharmacy
• Online Pharmacy

Based on the distribution channel, the market has been divided into hospital stores, retail pharmacy, and online pharmacy.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America's dominance in the cancer cachexia market is attributed to its robust healthcare infrastructure, high prevalence of chronic diseases, and significant investments in medical research and innovation, which together drive demand for healthcare products and services.

Global Cancer Cachexia Market Trends:

The aging demographic in many developed countries, including North America and parts of Europe, is a significant driver. As individuals age, the risk of cancer diagnosis increases, and older cancer patients are more susceptible to developing cachexia. This demographic shift is expected to further boost the demand for cachexia management and treatment options.

Additionally, growing awareness among healthcare professionals about the importance of early diagnosis and management of cancer cachexia is a driving factor. As healthcare providers become more attuned to recognizing cachexia symptoms, there is a greater likelihood of early intervention and treatment, contributing to the growth of the market.

Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

This release was published on openPR.